Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus YAELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus YAELA.
NORLESTRIN 21 2.5/50 vs YAELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Yaela is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity, contributing to contraceptive efficacy and reducing fluid retention.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
The standard adult dose of Yaela (ethinyl estradiol/levonorgestrel) for oral contraception is 1 tablet (containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) taken orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Terminal elimination half-life is 12 ± 3 hours (range 8-16 hours) in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Renal excretion of unchanged drug accounts for approximately 70% of the administered dose; biliary/fecal excretion accounts for 30%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive